Trial Profile
A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Tisagenlecleucel (Primary) ; Cyclophosphamide; Cytarabine; Etoposide; Fludarabine; Tocilizumab
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms CASSIOPEIA
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 23 Sep 2023 This trial has been completed in Finland, according to European Clinical Trials Database record.
- 11 Aug 2023 This trial has been suspended in Spain and Norway, according to European Clinical Trials Database record.
- 11 Aug 2023 The trial has been restarted in Sweden, according to European Clinical Trials Database record.